Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age40-69
SponsorUniversity of Virginia
About this trial
The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
Eligibility criteria
Qualifiers
• Female
40 to 69 years
Previous normal mammogram (BI-RADS 1 or 2) showing heterogeneous or extremely dense breast tissue within last 24 months
Scheduled for screening mammogram as part of the patient's clinical care
Disqualifiers
• No mammogram within last 24 months
Fatty or scattered fibroglandular tissue on last mammogram
History of allergy to iodinated contrast
History of renal disease or renal function abnormalities
Trial design
Treatments tested in this trial
- Contrast-enhanced spectral mammography (CESM)
Treatment groups
210 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov